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Abstract 
Review on human SLC1A5, with data on 
DNA/RNA, on the protein encoded and 
pathological and physiological implications. 
Identity 
Other names: AAAT, ASCT2, ATBO, M7V1, 
M7VS1, R16, RDRC 
HGNC (Hugo): SLC1A5 
Location: 19q13.32 
Local order: Orientation: minus strand. 
DNA/RNA 
Description 
The SLC1A5 gene, located at 19q13.3, counts 
28692 nucleotides with 8 exons. It has been found 
in 56 different organisms (NCBI). The gene 
encodes a protein involved in sodium-dependent 
neutral amino acid transport (Kekuda et al., 1996; 
Pingitore et al., 2013). 
Transcription 
Three isoforms (transcripts) are reported either on 
NCBI and Ensembl databases for SLC1A5 human 
gene, deriving from different translation start. They 
differ in length, particularly at 5' extremity. The 
first variant NM_005628 represents the longest 
transcript, constituted by 2873 nucleotides and 8 
exons. This transcript encodes a peptide of 541 
amino acids. The second variant NM_001145144 is 
constituted by 1737 nucleotides and differs in the 5' 
UTR from the variant NM_005628.  
In NM_001145144 the translation starts 
downstream the third exon generating a shorter 
peptide of 313 aa.  
The third isoform NM_ 001145145 has 1927 
nucleotides and lacks the first exon. It presents a 
different translation start at 5', coding a peptide of 
339 amino acids. A longer transcript, 
XM_005259167, is reported only in NCBI 
database.  
It has been identified by automated computational 
analysis. More than 400 SNP(s), both in coding and 
non-coding regions of the SLC1A5 gene, are 
reported in dbSNP database (dbSNP). More than 40 
are responsible of amino acid substitutions with 
unknown significance. Only the variant SLC1A5-
P17A (rs3027956) is associated with breast cancer 
(Savas et al., 2006). A region constituted by 907 bp 
upstream of the ASCT2 gene possesses promoter 
activity (Bungard and McGivan, 2004). In this 
region the following putative elements have been 
identified: an amino acid-regulatory element, a 
consensus site for binding of the transcription factor 
activator protein 1 (AP1) and a consensus binding 
sites for nuclear and hepatocyte nuclear factors. 
Pseudogene 
The gene is virtually present in all vertebrates. The 
better known orthologous of the human gene are 
those from rat, mouse and rabbit. Identity between 
the human and rat, mouse, rabbit are 79%, 82% and 
85%, respectively. 
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Figure 1. Isoforms of SLC1A5 gene. The three isoforms are present in the minus strand of the chromosome 19 in position 
19q13.3. NM_005628: isoform one, encodes for the longest peptide and is constituted by 8 exons; NM_001145144: isoform two, 
due to alternative splicing is characterized by only four exons; NM_ 001145145: isoform three presents seven exons. The 
nucleotide sequence is depicted as black lines. Coding nucleotides and untranslated (UTR) regions are indicated by red and 
white boxes, respectively. Exons are indicated by roman numbers. 
 
Protein 
Description 
541 amino acids; molecular mass 56598,34 Da. 
Human SLC1A5 is a permease (membrane 
transporter).  
The 3D structure is not available. Homology 
modeling highlights a structure similar to that of the 
glutamate transporter of P. horikoshii (1XFH). N- 
and C-terminal ends are intracellular. Potential site 
of N-glycosylation and phosphorilation are 
predicted.  
In the structural model, at least one glycosylation 
site is extracellular and the phosphorilation sites are 
intracellular (Fig. 2). 
Expression 
Human SLC1A5 has been originally named ASCT2 
from AlaSerCysTransporter2 or ATB0.  
The acronym ASCT2 is the most frequently used to 
designate this transport system.  
It is expressed in many tissues, including brain, 
(Bröer and Brookes, 2001; Deitmer et al., 2003; 
Gliddon et al., 2009).  
There is functional evidence of the expression of 
ASCT2 in kidney and intestine (Bode, 2001). 
Besides Caco-2 cells, apparently, also the HT-29 
intestinal cell line functionally expresses ASCT2 
(Kekuda et al., 1996; Kekuda et al., 1997). 
Poly(A)1 RNA isolated from several tissues of 
human origin revealed expression in placenta, lung, 
skeletal muscle, kidney, and pancreas (Kekuda et 
al., 1996). 
Localisation 
The protein is localized in the plasma membrane. 
Function 
Transport mediated by the human ASCT2 has been 
originally studied in intact cell systems over-
expressing the transport protein (Kekuda et al., 
1996; Kekuda et al., 1997).  
Recently, hASCT2 was over-expressed in the yeast 
P. pastoris, purified and reconstituted in artificial 
phospholipid vesicles (proteoliposomes), in absence 
of other interfering transporters.  
All experimental systems concur in demonstrating 
that hASCT2 is an obligate exchanger of neutral 
amino acid.  
This antiport requires the presence of extracellular 
Na+ which cannot be substituted by Li+ or K+. The 
Na+ ex:amino acidex stoichiometry of the human 
transporter is likely to be 1:1. Competition studies 
on 3H-glutamine, 3H-threonine or 3H-alanine 
transport performed in cells indicated that other 
potential substrates of hASCT2 are valine, leucine, 
serine, cysteine, asparagine, methionine, isoleucine, 
tryptophan, histidine, phenylalanine. While 
glutamate, lysine, arginine along with MeAIB [α-
(methylamino)isobutyric acid] and BCH [2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid] 
are neither transported nor inhibit hASCT2. 
Experiments with radioactive compounds 
confirmed the competition data (Torres-Zamorano 
et al., 1998). In proteoliposomes, inhibition has 
been confirmed for most but not for all of the amino 
acids. Moreover, proteoliposome studies 
highlighted an asymmetric specificity for amino 
acids allowing to distinguish the amino acids 
inwardly transported (alanine, cysteine, valine, 
methionine) from those bi-directionally transported 
(glutamine, serine, asparagine, and threonine).  
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Figure 2. Homology structural model of hASCT2. Ribbon diagram viewing of the transporter from the lateral side. The model 
was built using the glutamate transporter Glpth from Pyrococcus horikoshii crystal structure (1XFH) as the template by Modeller 
V9.13. The homology model was represented using SpdbViewer 4.01. Asn 163 and 212, predicted as glycosilation sites, are 
highlighted in blue; Ser 183, 261 and Thr 206, 207, 329, predicted as phosphorilation sites are highlighted in red and orange, 
respectively. Prediction according to Scan Prosite. 
 
 
The functional asymmetry was also confirmed by 
the kinetic analysis of [3H]glutamine/glutamine 
antiport: different Km values were measured on the 
external and internal sides of proteoliposomes, 
0,097 and 1,8 mM, respectively. 
The SH reagents HgCl2, mersalyl and pOHMB 
potently inhibited hASCT2 mediated transport 
(Pingitore et al., 2013). 
The physiological role of hASCT2 consists in 
providing cells with some neutral amino acids 
exporting others on the basis of the metabolic need 
of cells consistently with the intra and extracellular 
amino acid concentrations. In brain, particularly, 
hASCT2 contributes to glutamine homeostasis of 
neurons and astrocytes. On the basis of experiments 
performed with animal models, it was hypothesized 
that hASCT2 mediates efflux of glutamine from 
astrocytes, a process that is critical for the 
functioning of the glutamate-glutamine cycle to 
recover synaptically released glutamate in exchange 
with glutamine efflux (Bröer et al., 1999). The 
glutamine-glutamate cycle has been shown also in 
placenta. Glutamine crosses the placenta and enters 
the fetal liver where it is deamidated to glutamate. 
About 90% of glutamate generated by the liver is 
taken up by the placenta and used in the 
metabolism. The glutamine-glutamate cycle 
between the placenta and the fetal liver is 
obligatory for the generation of NADPH in the 
placenta (Torres-Zamorano et al., 1998). Among 
other functions reported for hASCT2 there is the 
regulation of mTOR pathway, translation and 
autophagy. The transporter regulates an increase in 
the intracellular concentration of glutamine which 
is then used by another plasma membrane 
transporter, named LAT1 (SLC7A5) (Galluccio et 
al., 2013) as efflux substrate to regulate the uptake 
of extracellular leucine with subsequent activation 
of mTORC1 (Nicklin et al., 2009). Moreover, it has 
been proposed that a group of retroviruses 
specifically uses the hASCT2 as a common cell 
surface receptor following a co-evolution 
phenomenon. The orthologous murine transporter 
mASCT2 is inactive as a viral receptor (Marin et 
al., 2003). 
Implicated in 
Molecular basis of cancerogenesis 
Note 
Tumor cells acquire altered metabolism. Due to 
these changes, the expression of membrane 
transporters involved in providing nutrients is 
altered. The plasma membrane transporter for 
glutamine ASCT2 has been clearly associated to 
cancer development and progression, together with 
another amino acid membrane transporter, LAT1 
specific for glutamine and other neutral amino acids 
(Fuchs and Bode, 2005). The energetic needs of 
cancer cells are different from normal ones due to 
the Warburg effect. According to this phenomenon 
ATP derives from anaerobic glycolisis bypassing 
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mitochondrial function (Ganapathy et al., 2009). In 
this scenario glutamine provided by means of 
ASCT2 and LAT1 transport function sustains tumor 
growth and signaling through mTOR pathway 
(Nicklin et al., 2009).  
The importance of ASCT2 in this network is 
revealed by induction of apoptosis when silencing 
its gene in human hepatoma cells (Fuchs et al., 
2004).  
In the following paragraphs specific examples of 
human cancers are reported. 
Prostate cancer 
Note 
Tissue microarray technology (TMA) has been used 
for studying ASCT2 in normal prostatic tissue, in 
benign prostatic hyperplasia and in prostate 
adenocarcinoma.  
In particular, a negative prognosis and a shorter 
time of recurrence for adenocarcinoma were 
associated to hASCT2 expression. Moreover, a 
more aggressive behavior of adenocarcinoma is 
described (Li et al., 2003). 
Colorectal carcinoma 
Note 
The expression of ASCT2 in colorectal carcinoma 
is normally associated to a decrease of percentage 
in patient survival (Witte et al., 2002). 
Neuroblastoma and glioma 
Note 
Neuroblastoma are childhood tumors very often 
benign. In some cases, however, neuroblastoma 
became malignant. One of the biological marker of 
this second category is the increased uptake of 
glutamine and other neutral aminoacids via ASCT2 
(Wasa et al., 2002). Human glioma C6 cells have 
been demonstrated to mediate uptake of glutamine 
via ASCT2 (Dolinska et al., 2003). 
Hepatoma 
Note 
Hepatocell carcinoma (HCC) is the most common 
malignant tumor of liver and one of the main cause 
of death. A study reported that higher rate of 
glutamine uptake via ASCT2 is a common feature 
of six examined hepatoma cell line (Bode et al., 
2002; Fuchs et al., 2004). 
Lung cancer 
Note 
ASCT2 has been found over expressed in lung 
cancer by proteomic approach and then confirmed 
at molecular level. Pharmacologic and genetic 
targeting of ASCT2 decreased cell growth and 
viability in lung cancer cells, an effect mediated in 
part by mTOR signaling (Hassanein et al., 2013). 
Breast cancer 
Note 
In breast cancer ASCT2 has been found over 
expressed together with other proteins related to 
glutamine metabolism like glutamminase and 
glutamate dehydrogenase (Kim et al., 2012).  
The study revealed that this metabolism is essential 
for sustaining breast cancer development and that 
the protein levels are different according to 
different subtypes of cancer. The subtype HER2 
showed the highest level of glutamine related 
proteins and that the basal-like breast cancers are 
more dependent on glutamine compared to luminal-
likeones. 
Other diseases 
Note 
Due to importance of glutamine in cell metabolism 
and the chromosomal localization of SLC1A5 gene, 
several association studies have been conducted to 
ascertain the involvement of hASCT2 in 
pathologies like cystinuria, cystic fibrosis, 
schizophrenia, Hartnup disorder and pre-eclampsia. 
However, no genetic associations have been 
revealed. 
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